News Archive

Enter a new treatment called 'phage therapy' and Greg Merril, CEO and co-founder of Adaptive Phage Therapeutics in Gaithersburg.

A unique feature of the MII program is the introduction of university “site miners” to facilitate the application process for faculty inventors. These commercialization experts support faculty with preparing proposals and advocate for projects in the review process. UMBC site miner David Fink

IBBR receives TEDCO MII Funding

Linshom announced today U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s first product, a small, non-invasive respiratory monitor that addresses the growing need for continuous respiratory monitoring for patients susceptible to respiratory depression and compromise.

The visual vocabulary tool was awarded $25,000 in Google credit in recognition of its innovative approach as it moves into its next stage of growth

Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced the company has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) in the

Datakwip, a building analytics software company in Frederick, Maryland, was internationally recognized in CEMEX Ventures top 50 most promising start-up companies working in construction technology. CEMEX Ventures, Boston Consulting Group (BCG) and Tracxn recently announced their list of the 50 most

Retired Maj. Gen. Linda L. Singh, former adjutant general of the Maryland National Guard, has joined Towson University as its first leader-in-residence, the university announced Monday.

Retired Major General Linda Singh was just appointed as interim Executive Director/Chief Executive Officer (ED/CEO) for TEDCO as of January 2020.

Experimental Nanoformulation Outperforms FDA-Approved Treatment for Metastatic Breast Cancer, Increasing Survival in Animal Studies

Maryland Technology Development Corporation (TEDCO) is once again accepting applications from startups seeking investment from several of its funds that were put on hold in the middle of 2019.

The company is developing phage-based therapies designed to target specific bacteria strains, as contrasted with antibiotics, which target multiple types of bacteria.

The Maryland Technology Development Corp. and the National Institute of Standards and Technology awarded four companies a total of $448,000 to develop NIST-licensed technologies for the market, TEDCO announced Tuesday.